February 4, 2022. Following PMI's acquisition of Vectura, the International Respiratory Society banned researchers associated with tobacco companies from publishing in its journals, Nature.com reported.
When Philip Morris International (PMI) took over drug company Vectura last year, the reaction of health bodies including the American Thoracic Society (ATS), the European Respiratory Society and the International Union against TUBERCULOSIS and Lung Disease described the move as "highly unethical and inappropriate"
The Global Respiratory Society has banned any researchers directly funded by tobacco companies from publishing in its journals, and that has now been extended to researchers working for companies owned by tobacco companies, Nature.com reported.
Gregory Downey, a pulmonologist at the University of Colorado Denver and ATS chair-elect, said Vectura, which has been making drugs for asthma and smoking-related respiratory diseases and is now owned by a tobacco company, was "the ultimate conflict between the two sides." Interest."
In response, Moira Gilchrist, vice president of strategy and science communication at PMI in Lausanne, Switzerland, said the company would not abuse Vectura's technology and criticised the ban on researchers.
"We openly welcome and encourage legitimate criticism and debate about the transformation of our business, but we should pause to consider the implications when this morphs into an active rejection of scientists and an attempt to prevent the prescribing of proven drugs for patients," she said.

